Sangamo Therapeutics, Inc.
0.12USD
+0.0000 (+0.00%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on SGMOQ.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 111.3M | 176.2M | 57.8M | 39.6M | 0.0 | 0.0 |
| Q1 | 28.2M | 158.0M | 481.0K | 6.4M | 1.4M | — |
| Q2 | 29.4M | 6.8M | 356.0K | 18.3M | — | — |
| Q3 | 26.5M | 9.4M | 49.4M | 581.0K | 0.0 | — |
| Q4 | 27.2M* | 2.0M* | 7.6M* | 14.2M* | — | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -1.25 | -1.48 | -.490 | -.440 | — | -.032 |
| Q1 | -.300 | .120 | -.270 | -.140 | -.080 | — |
| Q2 | -.290 | -.660 | -.180 | -.080 | — | — |
| Q3 | -.340 | -.590 | .040 | -.110 | — | — |
| Q4 | -.337* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.346* |
| -.116* |
| -.134* |
| — |
| — |
Debt level and coverage